Assessment of neopterin and indoleamine 2,3-dioxygenase activity in patients with seasonal influenza: A pilot study.
IDO
Influenza
Neopterin
biomarker
indoleamine 2,3-dioxygenase
outcome
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
06
07
2019
revised:
12
08
2019
accepted:
15
08
2019
pubmed:
7
9
2019
medline:
17
3
2020
entrez:
7
9
2019
Statut:
ppublish
Résumé
Seasonal influenza is an important cause of morbidity and mortality worldwide. Immune activation after stimulation with interferon-gamma leads to increased production of neopterin but also results in increased tryptophan catabolism through indoleamine 2,3-dioxygenase (IDO). Our pilot study determined neopterin serum levels and IDO activity in patients with influenza infection and investigated whether neopterin is linked to clinical outcome parameters (mortality ≤30 days, acute cardiac events (ACE) length of hospitalization, ICU admission). Neopterin concentrations were analyzed in serum samples of 40 patients with a confirmed diagnosis of influenza infection and in-hospital treatment for >24 hours. Data were compared to values of 100 healthy blood donors and 48 age-matched pneumonia patients. In a subgroup of 14 patients, tryptophan and kynurenine concentrations, as well as kynurenine-to-tryptophan ratio, were analyzed. In all influenza patients, neopterin concentrations were increased and significantly higher compared to those determined in patients with pneumonia and healthy controls. Positive correlations between the duration of hospitalization and neopterin were found. Significantly higher levels of kynurenine, kynurenine-to-tryptophan ratio, and lower levels of tryptophan were seen in influenza patients compared to healthy controls. Neopterin seems to be related to the course of the disease and could be a valuable biomarker to identify patients at an elevated risk of a worsened outcome; however, further prospective validation studies are needed to support the here presented preliminary results.
Sections du résumé
BACKGROUND
Seasonal influenza is an important cause of morbidity and mortality worldwide. Immune activation after stimulation with interferon-gamma leads to increased production of neopterin but also results in increased tryptophan catabolism through indoleamine 2,3-dioxygenase (IDO). Our pilot study determined neopterin serum levels and IDO activity in patients with influenza infection and investigated whether neopterin is linked to clinical outcome parameters (mortality ≤30 days, acute cardiac events (ACE) length of hospitalization, ICU admission).
METHODS
Neopterin concentrations were analyzed in serum samples of 40 patients with a confirmed diagnosis of influenza infection and in-hospital treatment for >24 hours. Data were compared to values of 100 healthy blood donors and 48 age-matched pneumonia patients. In a subgroup of 14 patients, tryptophan and kynurenine concentrations, as well as kynurenine-to-tryptophan ratio, were analyzed.
RESULTS
In all influenza patients, neopterin concentrations were increased and significantly higher compared to those determined in patients with pneumonia and healthy controls. Positive correlations between the duration of hospitalization and neopterin were found. Significantly higher levels of kynurenine, kynurenine-to-tryptophan ratio, and lower levels of tryptophan were seen in influenza patients compared to healthy controls.
CONCLUSIONS
Neopterin seems to be related to the course of the disease and could be a valuable biomarker to identify patients at an elevated risk of a worsened outcome; however, further prospective validation studies are needed to support the here presented preliminary results.
Identifiants
pubmed: 31489989
doi: 10.1111/irv.12677
pmc: PMC6800299
doi:
Substances chimiques
Biomarkers
0
Indoleamine-Pyrrole 2,3,-Dioxygenase
0
Kynurenine
343-65-7
Neopterin
670-65-5
Tryptophan
8DUH1N11BX
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-609Informations de copyright
© 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
PLoS One. 2013 Jun 13;8(6):e66546
pubmed: 23785507
Atherosclerosis. 1994 Apr;106(2):263-71
pubmed: 8060386
Influenza Other Respir Viruses. 2019 Nov;13(6):603-609
pubmed: 31489989
Lancet Infect Dis. 2009 Oct;9(10):601-10
pubmed: 19778762
Open Forum Infect Dis. 2017 Oct 25;5(1):ofx228
pubmed: 29322062
Life Sci. 1987 Jul 20;41(3):273-80
pubmed: 3110526
J Nutr. 2016 Sep;146(9):1801-6
pubmed: 27489009
JAMA Cardiol. 2016 Jun 1;1(3):274-81
pubmed: 27438105
Clin Microbiol Infect. 2011 Feb;17(2):235-7
pubmed: 20384708
Redox Rep. 1999;4(5):199-220
pubmed: 10731095
Clin Infect Dis. 2005 Mar 15;40(6):853-8
pubmed: 15736019
Mol Med Rep. 2018 Apr;17(4):4867-4873
pubmed: 29393500
Diagn Microbiol Infect Dis. 2007 Oct;59(2):131-6
pubmed: 17662560
Crit Rev Clin Lab Sci. 1992;29(3-4):307-41
pubmed: 1489521
J Infect. 2009 Feb;58(2):123-30
pubmed: 19073345
Clin Chem. 1997 Dec;43(12):2424-6
pubmed: 9439467
Proc Natl Acad Sci U S A. 1979 Aug;76(8):4084-6
pubmed: 291064
Kidney Int Suppl. 1994 Nov;47:S8-11
pubmed: 7869677
J Infect. 2006 Sep;53(3):152-8
pubmed: 16413058
N Engl J Med. 2018 Jan 25;378(4):345-353
pubmed: 29365305
J Clin Pharm Ther. 2001 Oct;26(5):319-29
pubmed: 11679022
Thromb Haemost. 2018 Apr;118(4):778-790
pubmed: 29458232
Clin Microbiol Infect. 2017 Apr;23(4):222-228
pubmed: 28216325
Nat Rev Microbiol. 2018 Jan;16(1):47-60
pubmed: 29081496
COPD. 2017 Jun;14(3):298-303
pubmed: 28548632
J Clin Virol. 2015 Jun;67:43-6
pubmed: 25959157
Clin Biochem. 2004 Aug;37(8):684-7
pubmed: 15302611
Am J Epidemiol. 2016 Feb 15;183(4):249-58
pubmed: 26823439
J Infect. 2008 Sep;57(3):249-59
pubmed: 18657324
J Interferon Res. 1986 Aug;6(4):389-96
pubmed: 3095441
J Infect Dis. 2016 Oct 15;214(8):1139-41
pubmed: 27095422